Cochlear (ASX:COH) Full Year 2024 Results
Key Financial Results
- Revenue: AU$2.24b (up 16% from FY 2023).
- Net income: AU$356.8m (up 19% from FY 2023).
- Profit margin: 16% (in line with FY 2023).
- EPS: AU$5.44 (up from AU$4.57 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cochlear EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.4%.
The primary driver behind last 12 months revenue was the Americas segment contributing a total revenue of AU$1.14b (51% of total revenue). The largest operating expense was General & Administrative costs, amounting to AU$897.6m (68% of total expenses). Explore how COH's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.
Performance of the Australian Medical Equipment industry.
The company's shares are down 9.7% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. See our latest analysis on Cochlear's balance sheet health.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:COH
Cochlear
Provides implantable hearing solutions for children and adults worldwide.
Flawless balance sheet with moderate growth potential.
